bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-20. Numbers and descriptions here follow the published literature rather than marketing material.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R | Highest reported agonist potency within the family |
| Secondary receptor activity | MC1R and MC3R | Lower potency than at MC4R |
| Elimination half-life | About 2 to 3 hours | Measured after subcutaneous administration |
| Plasma protein binding | Approximately 44 percent | Species- and assay-dependent |
| Route of administration | Subcutaneous injection | Reviewed product uses a single-use device |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Rhodium is one of the rarest elements in the Earth's crust, with less than one part per billion. Its rarity affects its price and its use in commercial applications. The concentration of rhodium in nickel meteorites is typically 1 part per billion. Rhodium has been measured in some potatoes with concentrations between 0.8 and 30 ppt.
Blood smear to evaluate cell morphology Iron panel to evaluate for concurrent iron deficiency JAK2 mutation testing Serum erythropoeitin (EPO) levels Oxygen saturation (usually via pulse oximetry or blood gas tests) or oxygen dissociation tests
Long-chain-fatty-acid—CoA ligase catalyzes the reaction between a fatty acid with ATP to give a fatty acyl adenylate, plus inorganic pyrophosphate, which then reacts with free coenzyme A to give a fatty acyl-CoA ester and AMP. If the fatty acyl-CoA has a long chain, then the carnitine shuttle must be utilized (shown in the table below): Acyl-CoA is transferred to the hydroxyl group of carnitine by carnitine palmitoyltransferase I, located on the cytosolic faces of the outer and inner mitochondrial membranes. Acyl-carnitine is shuttled inside by a carnitine-acylcarnitine translocase, as a carnitine is shuttled outside. Acyl-carnitine is converted back to acyl-CoA by carnitine palmitoyltransferase II, located on the interior face of the inner mitochondrial membrane. The liberated carnitine is shuttled back to the cytosol, as an acyl-carnitine is shuttled into the matrix. If the fatty acyl-CoA contains a short chain, these short-chain fatty acids can simply diffuse through the inner mitochondrial membrane.
The new 27th district stretches across the Coastal Bend, from downtown Corpus Christi and Port Aransas in the south, along with Victoria and the rural fringes of the Greater Houston area including Brenham, Bay City and Sealy, extending westward to La Grange along with the southern and eastern suburbs of Austin including Bastrop, Kyle and Lockhart along with an eastern sliver of Travis County (including the Circuit of the Americas). The incumbent is Republican Michael Cloud, who was re-elected with 66.0% of the vote in 2024. A plurality White district whose voting age population is more than 40% Hispanic, Donald Trump won 60% of the vote and Ted Cruz 57.1% in 2024.
Sources: en.wikipedia.org
=== Asthenia vs. myasthenia === Asthenia or asthaenia (Greek: ἀσθένεια, literally lack of strength but also disease) is a medical term referring to a condition in which the body lacks or has lost strength either as a whole or in any of its parts. It is a poorly defined condition that can include true or primary muscle weakness or perceived muscle weakness. For perceived muscle weakness, asthenia has been described as the feeling of weak or tired muscles in the absence of muscle weakness, that is the muscle can generate a normal amount of force but it is perceived as requiring more effort. General asthenia occurs in many chronic wasting diseases (such as tuberculosis and cancer), sleep disorders or chronic disorders of the heart, lungs or kidneys, and is probably most marked in diseases of the adrenal gland. Moreover, asthenia can be a symptom of mast cell activation syndrome (MCAS). Asthenia may be limited to certain organs or systems of organs, as in asthenopia, characterized by ready fatiguability. Asthenia is also a side effect of some medications and treatments, such as Ritonavir (a protease inhibitor used in HIV treatment). Differentiating psychogenic (perceived) asthenia and true asthenia from myasthenia is often difficult, and in time apparent psychogenic asthenia accompanying many chronic disorders is seen to progress into a primary weakness. Myasthenia or myasthaenia (my- from Greek: μυο meaning "muscle" + -asthenia [ἀσθένεια] meaning "weakness"), or simply muscle weakness, is a lack of muscle strength.
==== Martyrs ==== The decision as to whether martyrs had died for their faith in Christ and the consequent permission of veneration lay originally with the bishop of the place in which they had borne their testimony. The bishop inquired into the motive of the person's death and, on finding they had died a martyr, sent their name with an account of their martyrdom to other churches, especially neighboring ones, so that, in the event of approval by their respective bishops, the cultus of the martyr might extend to their churches also and that the faithful, as is said of Ignatius of Antioch in the "Acts" of his martyrdom "might hold communion with the generous martyr of Christ" (generoso Christi martyri communicarent). Martyrs whose cause, so to speak, had been discussed, and the fame of whose martyrdom had been confirmed, were known as proved (vindicati) martyrs. That word probably did not antedate the fourth century, when it was introduced into the Church at Carthage; but the fact is certainly older. In the earlier ages, therefore, this veneration was entirely local and passed from one church to another with the permission of their bishops. This is clear from the fact that in ancient Christian cemeteries there are found paintings of only those martyrs who had suffered in that neighborhood. It explains, also, the almost universal veneration very quickly paid to, e.g., Lawrence, Cyprian, and Sixtus II, who were killed by the Roman Emperor Valerian.
Testing during and for many weeks after a hemolytic episode will lead to false-negative results, as the G6PD-deficient RBC will have been excreted, and the young RBC (reticulocyte) will not yet be G6PD deficient. False-negative results will also be likely following any blood transfusions. For this reason, many hospitals wait three months after a hemolytic episode before testing for G6PD deficiency. Females should have their G6PD activity measured by a quantitative assay to avoid being misclassified by screening tests.
Sources: en.wikipedia.org
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.
Indirect evidence from animal studies supports central access, and the proposed mechanism requires it. Direct quantification in humans is limited. How much reaches specific brain regions remains an open question.
Published descriptions give a plasma half-life of roughly two to three hours after subcutaneous administration. Values vary with assay method and study population. The figure is an average rather than a fixed molecular property.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.